re,sharetips3 Jan 2017 17:51
Found some .
ouble ahead...but this trio should make money in 2017
By JOANNE HART, FINANCIAL MAIL ON SUNDAY
PUBLISHED: 23:45 GMT, 31 December 2016 | UPDATED: 10:02 GMT, 3 January 2017
e-mail
1
View comments
The markets ended 2016 on a high note, with the FTSE 100 Index rising to a new record of 7,143.
But there are considerable uncertainties about the year ahead, including Brexit negotiations and the early impact of Donald Trump’s presidency in the US.
Against this backdrop, Midas has chosen three very different tips for the year, each of which should prove resilient to the wider economic and political environment.
Trouble ahead? Markets are waiting to see what moves Donald Trump will make
Trouble ahead? Markets are waiting to see what moves Donald Trump will make
TIP 1: Creo Medical's safer and faster way to treat cancer
They are the second largest cancer killer in the world, so many countries, including Britain, have begun to offer screening procedures for bowel tumours to the over-55s. If any suspicious lumps and bumps are discovered, patients are whisked into hospital to have sections of their gut removed.
The procedure is invasive and high risk. About one in 20 people die within 30 days and among those who survive, many suffer from life-changing conditions following surgery.
Creo Medical has devised a safer, faster and much more precise alternative to gastro-intestinal surgery, whereby patients can be in and out of hospital in a day and still have potentially cancerous areas of their gut whipped away.
RELATED ARTICLES
Previous
1
Next
How to start 2017 in the best financial health: Pensions...
Nearly four in ten want house prices to fall next year - but...
English sparkling wine puts the fizz back into exports with...
Is it time for investors to forget the UK and look to...
SHARE THIS ARTICLE
Share
HOW THIS IS MONEY CAN HELP
How to choose the best (and cheapest) DIY investing Isa - and our pick of the platforms
The company joined AIM on December 9 at 76p a share, the price has risen to 81½p and should increase substantially as the group’s technology catches on and it becomes increasingly successful.
Creo was founded by Professor Chris Hancock, formerly senior engineer at Gyrus Medical, a UK company that was acquired for more than £920 million in 2007.
Gyrus was at the forefront of developing endoscopes, the long, thin tubes used for keyhole surgery.
Creo has now taken that technology several steps further, enabling keyhole procedures to be completed under local anaesthetic rather than general in an operating theatre.
The company’s devices are attached to existing endoscopes and can be used to treat not only problematic lumps in the gut but also tumours in the lung.
Lung cancer is the biggest cancer killer in the world, but treatment is predominantly via chemotherapy and radiotherapy, which cause considerable suffering and do not of